Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy
This is the first study in humans with GSK206136 to evaluate what effects: good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). Also the study aims to investigate the penetration of the drug in the human brain by using PET (Positron Emission Tomography) imaging technology
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536679 -
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
|
Phase 1 | |
| Completed |
NCT01424384 -
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
|
Phase 1 | |
| Completed |
NCT00513565 -
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00426608 -
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
|
Phase 1 | |
| Completed |
NCT01031186 -
First Time in Human Study
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |